Efbalropendekin alfa

N/A

Report date: 2025/02/27 16:12:24

Base Information

Drug NameEfbalropendekin alfa
Drug Alias NameIL15/IL15Ra-FcIL15/IL15Ra complex-Fc fusion protein XmAb24306IL15/IL15Ra-Fc fusion protein XmAb24306XmAb-24306RG-6323 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-15 inhibitorsInterleukin-15 receptor subunit alpha inhibitors
TargetsInterleukin-15 receptor subunit alphaInterleukin-15
Therapy Area/IndicationsSolid tumoursMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A